The US health authorities have recently announced a national emergency related to the use and abuse of opioids estimate by the CDC to cost the US alone $78.5 billion a year and leading to the death of 90 Americans a day . The addictive nature of our current gold standard pain killers for strong pain is central to this crisis and non-addictive alternative medication is urgently needed. Nanomerics NM127 directly addresses these needs.
Latest News and Events
Nanomerics' CEO Andreas Schatzlein is presenting new data on the use of the MET platform for the potential treatement of epilepsy at the Epitarget annual meeting in Warsaw (11-13 Oct). Epitarget (https://www.epitarget.eu) is a large European research consortium funded by the EU under the FP7 framework. Nanomerics has joined this consortium to support the CNS delivery of novel therapeutics developed by the consortium partners.
Join Nanomerics at Bio Europe 2017 from 6 - 9th November 2017 at Berlin’s CityCube. Nanomerics’ Chief Scientific Officer, Professor Ijeoma F. Uchegbu, will be in Berlin this year and so if you wish to meet with Nanomerics in Berlin, please email us.
At a glittering award ceremony held on the 13th of June 2017 at Manchester’s Midland Hotel, in the heart of the city, Nanomerics’ was awarded first prize in the Royal Society of Chemistry's Emerging Technologies Competition (Health). The award recognises the excellence associated with Nanomerics' MET platform, the technology underpinning Nanomerics’ business.
Storm clouds are gathering around pharmaceutical manufactures of opioid prescription pain killers in the US because these drugs are linked to an emerging healthcare crisis. Opiate based pain killers currently remain the 'gold' standard for the treatment of many causes of severe pain due the lack of safe and effective alternatives. This is despite their well known limitations and the high proportion of patients suffering from side effects. Increasingly, the abuse potential of these medicines is seen as a key driver for what FDA Commissioner Dr.
Nanomerics’ Chief Scientific Officer will be presenting on Nanomerics’ Molecular Envelope Technology (MET) at this year’s public outreach event for women scientists - Soapbox Science 2017 London (http://soapboxscience.org/soapbox-science-2017-london/). Soapbox science 2017 London will take place at London’s Southbank on Saturday 27th May from 2pm - 5pm. The event which is organised annually was over subscribed this year with 104 applications chasing 12 speaking slots.
Nanomerics will be presenting data on NM147, the MET-enabled oral form of Amphotericin B, at the 6th World Congress on Leishmaniasis (Worldleish 2017). The conference is organised by the WHO ColIaborating Centre for Leishmaniasis and DNDi and will be held in Toledo, Spain, from 16 to 20 May 2017.
Nanomerics has entered into a development agreement with California based NEMUS Bioscience, Inc. (OTCQB: NMUS), to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma.